Seamus Mulligan Buys 1,621 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Director Seamus Mulligan acquired 1,621 shares of the business’s stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $103.00 per share, with a total value of $166,963.00. Following the acquisition, the director now directly owns 101,621 shares of the company’s stock, valued at $10,466,963. This trade represents a 1.62% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Seamus Mulligan also recently made the following trade(s):

• On Friday, May 9th, Seamus Mulligan purchased 100,000 shares of Jazz Pharmaceuticals stock. The shares were purchased at an average price of $98.26 per share, with a total value of $9,826,000.00.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $106.59 on Thursday. The business’s 50-day moving average is $116.92 and its 200 day moving average is $122.00. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a market capitalization of $6.57 billion, a P/E ratio of 15.01, a P/E/G ratio of 1.04 and a beta of 0.38. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analysts’ expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The firm’s revenue was down .5% on a year-over-year basis. During the same period last year, the company earned $2.68 earnings per share. On average, equities research analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Barclays restated an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $182.79.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $25,000. Hurley Capital LLC bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at approximately $25,000. Quadrant Capital Group LLC increased its position in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. Elequin Capital LP raised its holdings in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 183 shares during the period. Finally, CoreFirst Bank & Trust bought a new stake in Jazz Pharmaceuticals in the fourth quarter worth $28,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.